PER 2.47% 8.3¢ percheron therapeutics limited

FGEN’s DMD drug targeting Fibrosis

  1. 293 Posts.
    lightbulb Created with Sketch. 808
    Fibrogen is a US$ 3.9bn company targeting fibrosis in DMD non ambulatory boys.. P2 results out last yr showed some improvement but not nearly as good as ANP’s..actually, not even close.

    Upper arm function and grip strength were measured by handheld myometry. Performance of the upper limb (PUL) scores decreased by only 1.53 points in patients treated with pamrevlumab compared to a decrease of 4.13 points in published results.It has 2 drugs and the 1 targeting DMD is also targeting 2 other indications.

    It has successful results in 1 indication but Only minimal improvements. See the attachment for more info.

    https://musculardystrophynews.com/pamrevlumab/

    It does have $600m cash in the bank which is the benefit of being able to raise funds with a larger market cap.
    It burns US$80m per quarter.

    I wanted to point FGEN out as you can see what valuations US companies can get even in development stages as FGEN has only 1 drug approved (Only $15m in sales) for any indication.

    FGEN pipeline:

    https://www.fibrogen.com/pipeline/

    Many investors seem not to be able to look past what is happening with ANP’s European P2b but by the end of 2021, ANP could possibly have a very strong pipeline for other indications.

    Good luck everyone.
 
watchlist Created with Sketch. Add PER (ASX) to my watchlist
(20min delay)
Last
8.3¢
Change
0.002(2.47%)
Mkt cap ! $74.82M
Open High Low Value Volume
9.0¢ 9.0¢ 8.2¢ $9.57K 112.6K

Buyers (Bids)

No. Vol. Price($)
2 124862 8.1¢
 

Sellers (Offers)

Price($) Vol. No.
8.9¢ 11000 1
View Market Depth
Last trade - 15.56pm 29/03/2024 (20 minute delay) ?
Last
8.2¢
  Change
0.002 ( 0.86 %)
Open High Low Volume
8.2¢ 8.3¢ 8.2¢ 31700
Last updated 15.55pm 29/03/2024 ?
PER (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.